The effects of exposure at constant (1 h) or exponentially decreasing concentrations of quinupristin/dalfopristin on biofilms of Gram-positive bacteria

Journal of Antimicrobial Chemotherapy

Volumn 46, Issue 1, 2000, Pages 61-67

  Gander, Sarah ^a   Finch, Roger ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; FLUCLOXACILLIN; GLYCOPEPTIDE; TEICOPLANIN; VANCOMYCIN; QUINUPRISTIN-DALFOPRISTIN; VIRGINIAMYCIN;

ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BIOFILM; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; DRUG COMBINATION; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGICAL EXAMINATION;

BIOFILMS; DRUG THERAPY, COMBINATION; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; VIRGINIAMYCIN;

EID: 0033910454     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/46.1.61     Document Type: Article

References (29)

1. Baquero, F. (1997). Gram-positive resistance: challenge for the development of new antibiotics. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 1-6.
2. Hill, R. L. R., Smith, C. T., Seyed-Akhavani, M. & Casewell, M. W. (1997). Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 23-8.
3. Kang, S. L. & Rybak, M. J. (1997). In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 33-9.
4. Low, D. E. & Nadler, H. L. (1997). A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 53-8.
5. Finch, R. G. (1994). Medical problems associated with biofilms. In Bacterial Biofilms and their Control in Medicine and Industry, (Wimpenny, J., Nichols, W., Stickler, D. & Lappin-Scott, H., Eds), pp. 88-92. Bioline, Chippenham.
6. Dasgupta, M. K. & Costerton, J. W. (1989). Significance of biofilm-adherent bacterial microcolonies on Tenckhoff catheters of CARD patients. Blood Purification 7, 144-55.
7. Dickinson, G. M. & Bisno, A. L. (1989). Infections associated with indwelling devices: concepts of pathogenesis; infections associated with intravascular devices. Antimicrobial Agents and Chemotherapy 33, 597-601.
8. Dickinson, G. M. & Bisno, A. L. (1989). Infections associated with indwelling devices: infections related to extravascular devices Antimicrobial Agents and Chemotherapy 33, 602-7.
9. Lowdin, E., Odenholt, I., Bengtsson, S. & Cars, O. (1996). Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model. Antimicrobial Agents and Chemotherapy 40, 2478-82.
10. BSAC Working Party Report. (1991). A guide to sensitivity testing. Journal of Antimicrobial Chemotherapy 27, Suppl. D, 1-50.
11. Hodgson, A. E., Nelson, S. M., Brown, M. R. W. & Gilbert, P. (1995). A simple in vitro model for growth control of bacterial biofilms. Journal of Applied Bacteriology 79, 87-93.
12. Bouanchaud, D. H. (1997). In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 15-21.
13. Mouton, J. W., Endtz, H. P., den Hollander, J. G., van den Braak, N. & Verbrugh, H.A. (1997). In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 75-80.
14. Williams, J. D., Maskell, J. P., Whiley, A. C. & Sefton, A. M. (1997). Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 41-6.
15. Appelbaum, P. C. (1996). Emerging resistance to antimicrobial agents in Gram-positive bacteria. Pneumococci. Drugs 51, Suppl. 1, 1-5.
16. Finch, R. G. (1996). Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use. Drugs 51, Suppl. 1, 31-7.
17. Pechère, J. C. (1996). Streptogramins. A unique class of antibiotics. Drugs 51, Suppl. 1, 13-9.
18. Boswell, F. J., Sunderland, J., Andrews, J. M. & Wise, R. (1997). Time-kill kinetics of quinupristin/dalfopristin on Staphylococcus aureus with and without a raised MBC evaluated by two methods. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 29-32.
19. Andrews, J. M. & Wise, R. (1994). The in-vitro activity of a new semi-synthetic streptogramin compound, RP 59500, against staphylococci and respiratory pathogens. Journal of Antimicrobial Chemotherapy 33, 849-53.
20. Fantin, B., Leclercq, R., Merle, Y., Saint-Julien, L., Veyrat, C., Duval, J. et al. (1995). Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 39, 400-5.
21. Fantin, B., Leclercq, R., Merle, Y., Saint-Julien, L., Duval, J. & Carbon, C. (1994). Influence of constitutive resistance to erythromycin on the activity of RP 59500 (quinupristin/dalfopristin) in experimental endocarditis due to Staphylococcus aureus. In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, 1994, Abstract B79, p. 150. American Society for Microbiology, Washington, DC.
22. Licata, L., Smith, C. E., Goldschmidt, R. M., Barrett, J. F. & Frosco, M. (1997). Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy 41, 950-5.
23. Löwdin, E., Odenholt, I. & Cars, O. (1998). In vitro studies of pharmocodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrobial Agents and Chemotherapy 42, 2739-44.
24. Pankuch, G. A., Jacobs, M. R. & Appelbaum, P. C. (1998). Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against Gram-positive and -negative organisms. Antimicrobial Agents and Chemotherapy 42, 3028-31.
25. Spangler, S. K., Lin, G., Jacobs, M. R. & Appelbaum, P. C. (1998). Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. Antimicrobial Agents and Chemotherapy 42, 1253-5.
26. Craig, W. A. & Gudmundsson, S. (1991). Postantibiotic effect. In Antibiotics in Laboratory Medicine, 3rd edn, (Lorian, V., Ed.), pp. 403-31. Williams & Wilkins, Baltimore, MD.
27. Rybak, M. J., Houlihan, H. H., Mercier, R.-C. & Kaatz, G. W. (1997). Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrobial Agents and Chemotherapy 41, 1359-63.
28. Hamilton-Miller, J. M. T. & Shah, S. (1997). Activity of quinupristin/dalfopristin against Staphylococcus epidermidis in biofilms: a comparison with ciprofloxacin. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 103-8.
29. Berthaud, N. & Desnottes, J.-F. (1997). In-vitro bactericidal activity of quinupristin/dalfopristin against adherent Staphylococcus aureus. Journal of Antimicrobial Chemotherapy 39, Suppl. A, 99-102.